Achieve Life Sciences Inc (ACHV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Achieve Life Sciences Inc (ACHV) has a cash flow conversion efficiency ratio of -0.649x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.93 Million) by net assets ($10.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Achieve Life Sciences Inc (ACHV) balance sheet quality index to measure how much of total assets are equity-financed.
Achieve Life Sciences Inc - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Achieve Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Achieve Life Sciences Inc (ACHV) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Achieve Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Achieve Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
InBody Co.Ltd
KQ:041830
|
0.032x |
|
Changhong Meiling Co Ltd
SHE:000521
|
-0.004x |
|
Shenzhen Kaizhong Precision Technology Co Ltd
SHE:002823
|
0.082x |
|
Hansen Technologies Ltd
AU:HSN
|
0.164x |
|
Alpargatas S.A
SA:ALPA3
|
0.075x |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
-0.008x |
|
Jana Small Finance Bank
NSE:JSFB
|
-0.575x |
|
Helen of Troy Ltd
NASDAQ:HELE
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Achieve Life Sciences Inc (1994–2025)
The table below shows the annual cash flow conversion efficiency of Achieve Life Sciences Inc from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Achieve Life Sciences Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $21.52 Million | $-49.47 Million | -2.299x | -61.38% |
| 2024-12-31 | $20.90 Million | $-29.77 Million | -1.424x | -108.43% |
| 2023-12-31 | $-1.45 Million | $-24.48 Million | 16.905x | +473.62% |
| 2022-12-31 | $8.30 Million | $-37.57 Million | -4.525x | -330.99% |
| 2021-12-31 | $28.04 Million | $-29.44 Million | -1.050x | -190.52% |
| 2020-12-31 | $37.29 Million | $-13.47 Million | -0.361x | +57.13% |
| 2019-12-31 | $18.05 Million | $-15.22 Million | -0.843x | -25.40% |
| 2018-12-31 | $15.80 Million | $-10.62 Million | -0.672x | +41.84% |
| 2017-12-31 | $7.88 Million | $-9.11 Million | -1.156x | +26.15% |
| 2016-12-31 | $18.97 Million | $-29.68 Million | -1.565x | -543.84% |
| 2015-12-31 | $37.44 Million | $-9.10 Million | -0.243x | +52.17% |
| 2014-12-31 | $34.06 Million | $-17.31 Million | -0.508x | +47.37% |
| 2013-12-31 | $37.21 Million | $-35.93 Million | -0.965x | -46.97% |
| 2012-12-31 | $66.21 Million | $-43.49 Million | -0.657x | -0.15% |
| 2011-12-31 | $30.89 Million | $-20.26 Million | -0.656x | -7.84% |
| 2010-12-31 | $44.12 Million | $-26.84 Million | -0.608x | -140.04% |
| 2009-12-31 | $22.96 Million | $34.88 Million | 1.519x | +232.16% |
| 2008-12-31 | $10.71 Million | $-12.31 Million | -1.149x | -57.15% |
| 2007-12-31 | $31.90 Million | $-23.34 Million | -0.731x | -59.96% |
| 2006-12-31 | $43.04 Million | $-19.68 Million | -0.457x | -92.89% |
| 2005-12-31 | $35.26 Million | $-8.36 Million | -0.237x | +69.07% |
| 2004-12-31 | $19.08 Million | $-14.62 Million | -0.766x | -49.34% |
| 2003-12-31 | $19.31 Million | $-9.91 Million | -0.513x | +22.41% |
| 2002-12-31 | $15.72 Million | $-10.40 Million | -0.661x | -876.37% |
| 2001-12-31 | $14.67 Million | $1.25 Million | 0.085x | +118.24% |
| 2000-12-31 | $8.51 Million | $-3.97 Million | -0.467x | -4570.19% |
| 1999-12-31 | $10.00 Million | $-100.00K | -0.010x | +99.27% |
| 1998-12-31 | $7.50 Million | $-10.30 Million | -1.373x | -1914.76% |
| 1997-12-31 | $18.50 Million | $1.40 Million | 0.076x | -63.68% |
| 1996-12-31 | $16.80 Million | $3.50 Million | 0.208x | +129.11% |
| 1995-12-31 | $10.90 Million | $-7.80 Million | -0.716x | -284.01% |
| 1994-12-31 | $-9.00 Million | $-3.50 Million | 0.389x | -- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more